Opinion on Pharmaceuticals and Healthcare

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Biogen Idec: BG-12 nudges closer to market

BG-12 looks set to become the second oral therapy to enter the multiple sclerosis (MS) market. While BG-12 offers a superior efficacy profile compared to market-leading interferons, it will face strong competition in the marketplace from Gilenya, the first oral treatment for MS, which launched in the US in October 2010.

Published By Datamonitor
29 Feb 2012
Expert View
Expert View

Tough competitive environment in Europe will hinder Dendreon's plans for Provenge

The European prostate cancer treatment space is currently characterized by economic austerity and strict regulation. Nevertheless, Dendreon is preparing to launch Provenge in the region in an attempt to counter the vaccine's disappointing US launch in April 2010. However, given the considerable hurdles for new cancer drugs in Europe, the company will be forced to rely on revenue growth elsewhere.

Published By Datamonitor
07 Feb 2012
Expert View
Expert View

Doubts over Gilenya's safety will benefit current and future competitors

Following reports of 11 deaths among patients, doubts have been cast over the safety of Novartis's Gilenya. The subsequent EMA review will likely boost sales of Gilenya's main competitors as physicians favor therapies with known safety profiles. In order to curb the impact of this high-profile review on future sales, Novartis would be well served to publish additional safety data for the drug.

Published By Datamonitor
25 Jan 2012
CommentWire
CommentWire

Pfizer/Medivation: end of the road for Dimebon in Alzheimer's

Top-line data show that the once-hyped Dimebon has again failed to improve Alzheimer's disease symptoms in a Phase III trial, leading to the discontinuation of all development of the drug. Despite this setback, Pfizer can look toward the development of bapineuzumab, its remaining late-stage Alzheimer's candidate, with cautious optimism.

Published By Datamonitor
17 Jan 2012
Expert View
Expert View

Bristol-Myers Squibb adds another dimension to hepatitis C pipeline

Bristol-Myers Squibb's profit machine Plavix - a drug worth $6.7bn in annual revenues in 2010, and an estimated $7.5bn in 2011 - is set to lose US data protection in May this year. With this in mind, the company has furthered its successful M&A philosophy of buying up pipeline-accretive drug developers through the $2.5bn acquisition of infectious diseases specialist Inhibitex.

Published By Datamonitor
10 Jan 2012
CommentWire
CommentWire

Insys Therapeutics: first-to-market sublingual fentanyl spray to enter a highly competitive space

Insys Therapeutics' Subsys represents the first oral spray formulation to gain US approval for the treatment of breakthrough cancer pain. The drug's rapid onset of analgesic action and ease of administration offer distinct clinical benefits to patients. However, Subsys will face strong competition from generic Actiq and other rapidly acting fentanyl brands upon launch.

Published By Datamonitor
06 Jan 2012
Expert View
Expert View

Significant deal activity in Asia Pacific during 2011

With some of the most populous and rapidly developing markets in the world and strengths in rapid, low-cost generics production, Asia Pacific has been attracting the attention of the international pharmaceutical industry and participating in significant deals and partnerships, according to the latest analysis by Datamonitor.

Published By Datamonitor
04 Jan 2012
CommentWire
CommentWire

AstraZeneca/Targacept: another nail in the coffin for TC-5214

New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.

Published By Datamonitor
20 Dec 2011
CommentWire
CommentWire

Sanofi: Aubagio's tolerability profile is key differentiator in light of lackluster efficacy

Phase III trial results have shown that Aubagio is no more effective than Rebif in the treatment of multiple sclerosis; however, it is potentially better tolerated. While Gilenya and other new treatments offer greater efficacy, Aubagio's favorable tolerability profile combined with a competitive price point should enable Sanofi to capture market share.

Published By Datamonitor
20 Dec 2011
CommentWire
CommentWire

Monoclonal antibodies dominate biosimilar pipelines

With global sales of over $300m in 2010, and sales potentially exceeding $3bn by 2015, biosimilars have become a key focus for drugmakers. Already a number of biosimilars have launched in developed markets, with hundreds of copy-biologics available in the emerging markets. Furthermore, Datamonitor has identified approximately 200 pipeline candidates, reflecting the growth potential of this market.

Published By Datamonitor
15 Dec 2011

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.